AT
ATRA.US Atara Biotherapeutics Inc
- Market cap
- USD 78.5M
- P/E
- -
- P/B
- 16.14x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is ATRA.US undervalued?
Graham numberThe Graham number of Atara Biotherapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Atara Biotherapeutics Inc fundamental analysis
No fundamental analysis for Atara Biotherapeutics Inc yet.
Atara Biotherapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Atara Biotherapeutics Inc
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. It also develops ATA3219, an allogeneic CAR T targeting…
Full company profileAtara Biotherapeutics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Atara Biotherapeutics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 3.55M | 20.3M | 63.6M | 8.57M | 129M | 121M | 3.16M |
| Gross Profit | -383K | -956K | -3.78M | -8.11M | -9.87M | 20.3M | -206M | -313K | 108M | 99.6M | 2.39M |
| Operating Income | -81.2M | -122M | -237M | -296M | -309M | -340M | -281M | -276M | -83.4M | 35.9M | -14.7M |
| EBITDA | -80.9M | -121M | -233M | -289M | -301M | -331M | -222M | -266M | -75.7M | 38.6M | -13.5M |
| Net Income | -79.0M | -119M | -231M | -291M | -307M | -340M | -228M | -276M | -85.4M | 32.7M | -14.9M |
| EPS | -69 | -100 | -132 | -142 | -104 | -91 | -56 | -65 | -11 | 2.57 | -0.98 |
| Balance Sheet | |||||||||||
| Total Assets | 264M | 218M | 392M | 343M | 588M | 468M | 376M | 166M | 109M | 20.2M | 18.6M |
| Total Liabilities | 10.2M | 39.9M | 53.0M | 52.2M | 126M | 189M | 250M | 265M | 206M | 58.7M | 56.5M |
| Shareholders' Equity | 254M | 178M | 339M | 291M | 462M | 280M | 127M | -99.2M | -97.3M | -38.5M | -37.9M |
| Cash & Short-term Investments | 256M | 166M | 310M | 259M | 501M | 371M | 243M | 51.7M | 42.5M | 8.48M | 9.92M |
| Total Debt | - | 500K | 738K | 15.7M | 15.0M | 28.3M | 71.7M | 57.9M | 43.8M | 52.8M | 9.57M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -60.0M | -87.5M | -180M | -236M | -181M | -221M | -270M | -193M | -68.7M | -50.9M | -9.72M |
| Capital Expenditure | 3.02M | 20.2M | 35.9M | 5.73M | 4.51M | 10.6M | 4.19M | 1.22M | 246K | 0.00 | 0.00 |
| Free Cash Flow | -63.0M | -108M | -216M | -241M | -185M | -231M | -275M | -194M | -69.0M | -50.9M | -9.72M |
| Ratios | |||||||||||
| ROE | -31.2% | -67.2% | -68.1% | -100.1% | -66.3% | -121.6% | -180.3% | - | - | - | - |
| ROA | -30.0% | -54.9% | -58.9% | -84.8% | -52.1% | -72.7% | -60.7% | -166.8% | -78.3% | 161.5% | -80.3% |
| Net Profit Margin | - | - | - | - | -8,632.3% | -1,672.3% | -359.1% | -3,220.9% | -66.2% | 27.1% | -472.9% |
| Debt to Equity | - | 0.00x | 0.00x | 0.05x | 0.03x | 0.10x | 0.57x | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Atara Biotherapeutics Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | USD 623K | 0.15 | - |
| 2021 | USD 1.24M | 0.33 | - |
| 2020 | USD 1.52M | 0.51 | - |
| 2019 | USD 6.70M | 3.26 | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:25 on Jun 20, 2024.
Who owns Atara Biotherapeutics Inc
- Insiders 16.75%
- Institutions 56.01%
- Public & others 27.24%
- Shares outstanding 10.2M
- Free float 4.69M
Top funds holding ATRA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 159K | 1.58% | 0.00% | Sep 2026 |
| Mackenzie GQE US Small Cap F8 | 56.1K | 0.56% | -2.66% | Aug 2026 |
| Fidelity Extended Market Index | 38.5K | 0.38% | -0.38% | Sep 2026 |
| iShares Micro-Cap ETF | 18.5K | 0.18% | 0.00% | Oct 2026 |
| Fidelity VIP Disciplined Small Cap Init | 16.2K | 0.16% | 0.00% | Aug 2026 |
| EA Bridgeway Ultra-Small Company Mkt ETF | 13.6K | 0.14% | 0.00% | Oct 2026 |
| Fidelity Total Market Index | 11.7K | 0.12% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 11.2K | 0.11% | 0.00% | Sep 2026 |
| Vanguard U.S. Eq Idx £ Acc | 4.65K | 0.05% | +219.64% | Sep 2026 |
| Vanguard MStar Inst Ttl StkMktIdxInstlPl | 2.84K | 0.03% | 0.00% | Sep 2026 |
| Vanguard Balanced Index Inv | 2.80K | 0.03% | 0.00% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 1.93K | 0.02% | -58.07% | Aug 2026 |
| Schwab Total Stock Market Index | 1.64K | 0.02% | 0.00% | Sep 2026 |
| 1290 VT Micro Cap K | 1.15K | 0.01% | 0.00% | Sep 2026 |
| JHVIT Total Stock Market Index I | 196.00 | 0.00% | -6.67% | Aug 2026 |
Top institutions holding ATRA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| EcoR1 Capital, LLC | 1.55M | 15.46% | +1,458.34% | Jun 2026 |
| Adage Capital Partners Gp LLC | 850K | 8.47% | +21.43% | Jun 2026 |
| Point72 Asset Management, L.P. | 688K | 6.85% | +254.01% | Jun 2026 |
| Redmile Group, LLC | 442K | 4.40% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 247K | 2.46% | +13.40% | Jun 2026 |
| Mackenzie Investments | 233K | 2.32% | -25.63% | Jun 2026 |
| BlackRock Inc | 84.5K | 0.84% | +6.88% | Jun 2026 |
| Geode Capital Management, LLC | 75.1K | 0.75% | +13.58% | Jun 2026 |
| Staley Capital Advisers Inc | 50.0K | 0.50% | 0.00% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 43.0K | 0.43% | +28.00% | Jun 2026 |
| Acadian Asset Management LLC | 38.8K | 0.39% | -70.33% | Jun 2026 |
| Jane Street Group LLC | 30.3K | 0.30% | -10.41% | Jun 2026 |
| State Street Corp | 26.5K | 0.26% | 0.00% | Jun 2026 |
| Northern Trust Corp | 16.6K | 0.17% | +34.45% | Jun 2026 |
| FMR Inc | 16.2K | 0.16% | 0.00% | Jun 2026 |
| XTX Topco Ltd | 15.3K | 0.15% | 0.00% | Jun 2026 |
| Bridgeway Capital Management, LLC | 14.0K | 0.14% | -57.17% | Jun 2026 |
| Millennium Management LLC | 12.7K | 0.13% | -73.41% | Jun 2026 |
| Citadel Advisors Llc | 10.2K | 0.10% | 0.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 9.18K | 0.09% | +0.10% | Jun 2026 |
Atara Biotherapeutics Inc company profile
- Company name
- Atara Biotherapeutics Inc
- Ticker
- ATRA.US
- Exchange
- USA Stocks
- Listed since
- Oct 16, 2014
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 14
- Fiscal year end
- December
- Address
- 1280 Rancho Conejo Blvd, Thousand Oaks, CA, United States, 91320
- Phone
- 805 623 4211
- Website
- atarabio.com
About Atara Biotherapeutics Inc
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. It also develops ATA3219, an allogeneic CAR T targeting CD19 intended to target B-cell malignancies and autoimmune diseases. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.
Atara Biotherapeutics Inc management
3- Dr. Anhco Nguyen Ph.D.President, CEO & Director · born 1973
- Mr. Kevin G. Sarney CPAInterim Chief Financial Officer · born 1965
- Mr. Jim SesicSenior Vice President of Regulatory Affairs